Effectiveness of Stereotactic RadioTherapy in Solid Primary Inoperable and Oligometastatic Cancer

Study of Effectiveness of Stereotactic Body RadioTherapy and Stereotactic RadioSurgery in Solid Primary Inoperable and Oligometastatic Cancer

The purpose of this study is to development of more effective treatment tactics of the stereotactic radiotherapy and radiosurgery alone and together with classic radiation therapy in primary inoperabel solid tumors and oligometastastatic cancer.

Despite the fact that of many investigations in the world clinical researches, the SRT of primary-inoperabel and metastatic solid tumors combined with conventional and conformal radiation therapy methods the possibility of the sequences, the optimal fractions of the regimes and doses which determines normal tissues toxic manifestations, implementation of prevention, have not been solved yet.

The conducted research works to study quality of life for improving the social status of patients with primary-inoperable and metastatic solid tumors, is not fully resolved.

Thus, preparing of highly effective treatment tactics in primary-inoperable and metastatic solid tumors, is one of the most important problems of modern clinical oncology and this fact gives grounds to carry out the planned research work.

Inclusion Criteria:

• Histologically confirmed primary-inoperable solid tumors or oligometastatic cancer.
• Acceptance of patient by surgeon as non-operabel or refusing of surgery.
• No more than 4 metastatic foci in irradiated organ.
• Karnofsky scale more than 60.
• Age ≥18 years.
• Estimated duration of life >3 months.
• Hemoglobin ≥ 8 g/dl.
• Absolute neutrophil count at least 1,500/mm^3.
• Platelet count at least 70,000/mm^3.
• Bilirubin no greater than 1.5 times normal.
• SGOT and SGPT no greater than 3 times normal.
• Creatinine less than 1.5 mg/dL. PT-INR/APTT less than 1.5.
• Last patients data no older than 1 month.
• No prior radiotherapy of same location.
• Prior chemottherapy more than 2 weeks ago.

Exclusion Criteria:

• Progression of primary site of metastatic cancer.
• Pregnancy or Breast-Feeding.
• Decompensated concomitant diseases.